ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "immunology"

  • Abstract Number: 1339 • ACR Convergence 2025

    Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors

    Romain Stammler1, Peter Chen2, Orianne Debeaupuis2, Lin Pierre Zhao1, Mirabelle Ruyer Thompson1, Eve Zakine1, Julien Rossignol1, Lauriane Goldwirt1, Thibault Comont3, Mael Heiblig4, Lionel Ades1, Marie Sebert1, Jean-sébastien Allain5, Julien Campagne6, Marie Anne Couturier7, Marina Cumin8, Marie Caroline Dalmas9, Guillaume Denis10, Cecile Devloo11, Adrien De Voeght12, Louis Drevon1, Pierre Duffau13, Sophie georgin-Lavialle14, Delphine Gobert1, Noemie Abisror15, Olivier Kosmider16, Fréderic Rieux-Laucat2, Estibaliz LAZARO17, Jean Guillaume Lopez18, Alexandre Maria19, Wladimir Mauhin20, Julie Merindol21, Claire Merlot22, Tristan Mirault1, Laurent Pascal23, François Perrin24, Emmanuel Raffoux1, Ramy Rahme25, Damien Roos-Weil1, Benjamin Terrier26, Benjamin Torreau27, Olivier Fain1, Pierre Fenaux1, Pierre Hirsch1, Vincent Jachiet1, Jerome Hadjadj1 and Arsène Mekinian28, 1Assistance Publique des Hôpitaux de Paris, Paris, France, 2Imagine Institute, Paris, France, 3Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, 4Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, 5Scorff-Lorient Hospital, Lorient, France, 6Hospital Robert Schuman, Metz, France, 7Centre Hospitalier Régional et Universitaire de Brest, Brest, France, 8Centre hospitalier de Libourne, Libourne, France, 9Strasbourg University Hospital Center, Strasbourg, France, 10Centre Hospitalier Rochefort, Rochefort, France, 11Centre hospitalier de Dieppe, Dieppe, France, 12CHU of Liège, Liège, Belgium, 13Groupe Hospitalier Saint-André, Bordeaux, France, 14Sorbonne university, Tenon hospital, DMU3ID, CEREMAIA, ERN RITA, Paris, France, 15Internal Medicine, CHU Saint-Antoine,, Paris, France, 16AP-HP, Hopital Cochin, Institut Cochin, CNRS UMR8104, INSERM U1016 Université Paris Cité Paris France., PARIS, France, 17Bordeaux University Hospital, Pessac, France, 18Dupuytren University Hospital, Limoges, France, 19Saint-Eloi Hospital, Montpellier, France, 20Croix Saint Simon Hospital, Paris, France, 21University Hospital of Nice, Nice, France, 22Centre hospitaliser d’Orléans, Orléans, France, 23Hôpital Saint-Vincent de Paul, Lille, France, 24Centre Hospitalier de Saint-Nazaire, Saint Nazaire, France, 25Assistance Publique des Hôpitaux de Paris, Bobigny, France, 26Cochin Hospital, Paris, France, 27Internal Medicine and Immunology, CHU Tours, Tours, France, 28Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i3), Saint-Antoine University Hospital, 75012 Paris, France, Paris, France

    Background/Purpose: Clonal hematopoiesis has emerged as a key contributor to systemic inflammation, bridging hematologic and immune-mediated inflammatory disorders (IMIDs). Isocitrate dehydrogenase 1 and 2 (IDH1/2)…
  • Abstract Number: 1004 • ACR Convergence 2025

    Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint

    Yang Yang1, Yusuke Miyashita2, Madison Mangin3, Kellen Winden1, Peter Nigrovic2 and Margaret Chang1, 1Boston Children's Hospital, Boston, MA, 2Boston Children's Hospital, Brookline, MA, 3Boston Children's Hospital, St Simons Island, GA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We…
  • Abstract Number: 0899 • ACR Convergence 2025

    Altered B cell Subsets Shared in Immune Checkpoint Inhibitor Associated Sicca Syndrome and Sjogren’s Disease

    Caroline Atlas1, Balakrishnan Kamaraj1, Omid Jamshidi1, Adam Mor1, Yevgeniya Gartshteyn2, Teja Kapoor3 and Robert Winchester1, 1Columbia University, New York, NY, 2Columbia University Medical Center, Glen Rock, NJ, 3Columbia University Irving Medical Center, New York, NY

    Background/Purpose: Sicca symptoms may develop in the setting of immune checkpoint inhibitor (ICI) therapy and are clinically indistinguishable from those encountered in Sjogren’s disease (SjD).…
  • Abstract Number: 0781 • ACR Convergence 2025

    Comprehensive mass cytometry analyses of disease-related cells in adult-onset Still’s disease

    Hiroto Yoshida1, Mayu Magi1, Hiroya Tamai2, Kotaro Matsumoto2, Keiko Yoshimoto2, Tetsuhiro Soeda1 and Yuko Kaneko2, 1Chugai Pharmaceutical Co., Ltd. Product Research Dept., Yokohama, Kanagawa, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Adult-onset Still's Disease (AOSD) is a rare autoinflammatory disorder characterized by high fever, rash, and arthritis. Although overactivation of macrophages, an increase in specific…
  • Abstract Number: 0008 • ACR Convergence 2025

    Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform

    Julia Manasson1, Liliana Sanmarco2, Alex Pellerin2, Maria Cecilia Ramello2, Agustin Plasencia2, Jordan Anderson2, Tobias Green2, Andita Newton2, Ryan Peckner2, Yi Xing2, Heather Vital3, Nathan Higginson-Scott2, John Sundy4, Kevin L. Otipoby2 and Ivan Mascanfroni2, 1Seismic Therapeutic, New York, NY, 2Seismic Therapeutic, Watertown, MA, 3Seismic Therapeutic, Lexington, MA, 4Seismic Therapeutic, Durham, NC

    Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
  • Abstract Number: 2665 • ACR Convergence 2025

    Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline

    Thomas Dörner1, Nan Shen2, Thomas Grader-Beck3, Caroline Walter4, Catherine Wioland4, Celine Rauld4, Patrick Schmutz4, Simone Riek4, Wolfgang Hueber5, CAROLE SIPS6, Stephen Oliver4, Carol Lau7, Claire Bonal6 and Isabelle Isnardi8, 1Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, 2Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), 3Johns Hopkins, Reisterstown, MD, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals, Basel, Switzerland, 6Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, 8Novartis, Gueberschwihr, France

    Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…
  • Abstract Number: 2168 • ACR Convergence 2025

    Training Objective Structured Clinical Examinations in a Clinical Immunology department: Expectations and Perceptions of Medical students at Graduating Level

    Aïcha Kante1, Damien Sène2, Venceslas Bourdin3, Dikélélé Elessa3, William Bigot3, Valentine Pagis3, Frédéric Truffinet3, Stéphane Mouly3 and Cloé Comarmond1, 1Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U942, Paris, France, 2Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, 3Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France

    Background/Purpose: Objective Structured Clinical Examinations (OSCEs) are based on various starting clinical scenarios conducted in a simulated environment that allow for the standardized assessment of…
  • Abstract Number: 1755 • ACR Convergence 2025

    Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways

    Zoya Qaiyum1, Michael Tang2, Shirin Soleimani3, Addison Pacheco2, Melissa Lim4, Fataneh Tavasolian4, Trevor Pugh3 and Robert Inman2, 1Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. We…
  • Abstract Number: 1314 • ACR Convergence 2025

    Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis

    Julia King1, Michael Duryee1, Punyasha Roul2, Katherine Wysham3, Grant Cannon4, Gary Kunkel5, John Richards6, Isaac Smith7, Beth Wallace8, Gail Kerr9, Andreas Reimold10, Pascale Schwab11, Daniel Anderson12, Wenxian Zhou13, Joshua Baker14, Ted Mikuls1, Bryant England1 and Tate Johnson1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 7Duke University Hospital, Durham, NC, 8Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 9Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 10Dallas VA Medical Center, Dallas, TX, 11VA Portland and Oregon Health & Science University, Portland, OR, 120587964, Durham, NC, 13University of Nebraska Medical Center, Bellevue, NE, 14University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in rheumatoid arthritis (RA), driven primarily by atherosclerotic CVD (ASCVD) and heart failure (HF). Malondialdehyde-acetaldehyde…
  • Abstract Number: 1003 • ACR Convergence 2025

    Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology 

    Yan Zhang1, Brittany Ross1, Aditi Upadhye1, Diana Galvan1, Shaun E Grosskurth1, Yanjie Bao1, Romina Riener1, Annabel Wang1, Aric Frantz1, Gregor B Adams1, Michael Rosenzweig1, Ramin Farzaneh-Far1, Priya Karmali1, Adrian I Bot1, Carl June2 and Haig Aghajanian1, 1Capstan Therapeutics, San Diego, CA, 2University of Pennsylvania, Philadelphia, PA

    Background/Purpose: A major objective in autoimmunity is immune reset, requiring autoreactive B cell depletion in tissues. We designed an in vivo CAR product candidate (CPTX2309)…
  • Abstract Number: 0898 • ACR Convergence 2025

    Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage

    Carley Tasker1, Nicholas Giovannone2, Nyanza Rothman2, Sofia Caruso2, Julia Provino2, Laura Johnsen2, Johanna Napetschnig2, Jamie Orengo1, Christos Kyratsous2, Andre Limnander1, Katherine Cygnar2 and Andrew Baik2, 1Regeneron, Tarrytown, NY, 2Regeneron Pharmaceuticals, Tarrytown

    Background/Purpose: Development of effective targeting strategies to eliminate sources of antibody production presents utility in the treatment of autoimmune diseases driven by pathogenic autoantibodies. Furthermore,…
  • Abstract Number: 0747 • ACR Convergence 2025

    Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis

    Irene Carrión-Barberà1, Ryan D. Stultz2, David Cuthbertson3, Nader Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Paul Monach8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Kenneth Warrington12, Peter Merkel7 and Christian Lood13, 1Department of Rheumatology. Hospital del Mar, Barcelona, Spain, 2University of Washington, Division of Rheumatology, Seattle, WA, 3University of South Florida, Tampa, 4Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Moreland Hills, OH, 7University of Pennsylvania, Philadelphia, PA, 8VA Boston Healthcare System, Boston, MA, 9University of Colorado, Denver, CO, 10Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, ROCHESTER, MN, 13University of Washington, Division of Rheumatology, Seattle

    Background/Purpose: Macrophages play a central role in the pathogenesis of large-vessel vasculitides, including giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Characterizing patterns of macrophage…
  • Abstract Number: L11 • ACR Convergence 2024

    Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification

    May Choi1, Farbod Moghaddam1, Mohammad Sajadi1, Ann E. Clarke1, Sasha Bernatsky2, Karen Costenbader3, Irene Chen4, Murray Urowitz5, John Hanly6, Caroline Gordon7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Jorge Sanchez-Guerrero10, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul Fortin15, Dafna Gladman16, Ian Bruce17, Michelle Petri18, Ellen Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Graciela Alarcón24, Ronald Van Vollenhoven25, Cynthia Aranow26, Meggan Mackay26, Guillermo Ruiz-Irastorza27, S. Sam Lim28, Murat Inanç29, Kenneth Kalunian30, Soren Jacobsen31, Christine Peschken32, Diane Kamen33, Anca Askanase34, Marvin Fritzler35 and Mina Aminghafari1, 1University of Calgary, Calgary, AB, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 4UC Berkeley and UCSF, Berkeley, CA, 5Self employed, Toronto, ON, Canada, 6Dalhousie University, Halifax, NS, Canada, 7University of Birmingham, Birmingham, United Kingdom, 8Hanyang University Medical Center, Seoul, South Korea, 9The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, 10Krembil Research Institute, Toronto, ON, Canada, 11Cedars Sinai Medical Center, Studio City, CA, 12Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 13University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, 16University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 17Queen's University Belfast, Belfast, United Kingdom, 18Johns Hopkins University School of Medicine, Baltimore, MD, 19SUNY Downstate Health Sciences University, New York, NY, 20UNC physician network, Chapel Hill, NC, 21Northwestern University, Chicago, IL, 22Allegheny Health Network, Pittsburgh, PA, 23Lund University, Lund, Sweden, 24The University of Alabama at Birmingham, Oakland, CA, 25Amsterdam UMC, Amsterdam, Netherlands, 26Feinstein Institutes for Medical Research, New York, NY, 27Biobizkaia Health Research Institute, Bilbao, Spain, 28Emory University, Atlanta, GA, 29Istanbul University, Istanbul, Turkey, 30UC San Diego, La Jolla, CA, 31Rigshospitalet, Copenhagen, Denmark, 32University of Manitoba, Winnipeg, MB, Canada, 33Medical University of South Carolina, Johns Island, SC, 34Columbia University Medical Center, New York, NY, 35Mitogen Diagnostics Corp, Calgary, AB, Canada

    Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
  • Abstract Number: 0240 • ACR Convergence 2024

    Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Asia-Sophia Wolf2, Taissa M. Kasahara3, Kristin H. Bjørlykke4, Ingrid Jyssum5, Joseph Sexton5, Anne Therese Tveter5, Guri Solum2, Ingrid Fadum Kjønstad2, Ingrid E. Christensen5, Tore K. Kvien6, Jørgen Jahnsen7, Espen A. Haavardsholm1, Ludvig A. Munthe8, Sella A. Provan5, John Torgils Vaage8, Kristin K. Jørgensen4, Gunnveig Grødeland8, Siri Mjaaland2, Silje W. Syversen9 and Guro L. Goll9, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 3University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 7Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 8Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
  • Abstract Number: 0962 • ACR Convergence 2024

    Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis

    Parker Jones1, Salina Dominguez2, Miranda Gurra3, Gaurav Gadhvi4, Tyler Therron2, Kathleen Aren5, Carla Cuda3, Monique Hinchcliff6, Harris Perlman3, Hadijat Makinde3 and Deborah Winter7, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University, Chicago, IL, 4University of Michigan, Ann Arbor, MI, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Yale School of Medicine, Westport, CT, 7Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by multiorgan fibrosis. The two main subtypes are diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology